Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination With Bevacizumab Versus Sunitinib in Renal Cell Carcinoma

Nature Medicine - United Kingdom
doi 10.1038/s41591-018-0235-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2013English

Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma in Vivo With Susceptibility Contrast MRI

Cancer Research
Cancer ResearchOncology
2017English

Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma

Current Oncology
Oncology
2010English

Publisher Correction: Renal Capsular Invasion Is a Prognostic Biomarker in Localized Clear Cell Renal Cell Carcinoma

Scientific Reports
Multidisciplinary
2018English

A Case of Metastatic Renal Cell Carcinoma and Bile Duct Carcinoma Treated With a Combination of Sunitinib and Gemcitabine

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Cost-Effectiveness and Cost-Utility Analysis of Sunitinib Versus Sorafenib and Bevacizumab + Interferon-Alfa as First-Line Treatment for Metastatic Renal Cell Carcinoma in Ecuador

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Bevacizumab, Sorafenib Tosylate, Sunitinib and Temsirolimus for Renal Cell Carcinoma: A Systematic Review and Economic Evaluation

Health Technology Assessment
MedicineHealth Policy
2010English

Cox-2 Inhibition Enhances the Activity of Sunitinib in Human Renal Cell Carcinoma Xenografts

British Journal of Cancer
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy